We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Novel, Urine-Based, Molecular Test Assesses Risk of Aggressive Prostate Cancer

By LabMedica International staff writers
Posted on 14 Jul 2022
Print article
Image: miR Sentinel Prostate Cancer Test is now commercially available (Photo courtesy of miR Scientific)
Image: miR Sentinel Prostate Cancer Test is now commercially available (Photo courtesy of miR Scientific)

Prostate cancer is prevalent and deadly. It represents the highest number of new cancer cases diagnosed annually and is the second leading cause of cancer deaths among men. Early detection and the ability to identify high grade disease early are key to effective disease management. Until now, no effective, accurate and non-invasive tests have been developed for the early detection and grade classification of prostate cancer. Now, a novel, urine-based, molecular test assesses the risk of aggressive prostate cancer by analyzing small non-coding RNA using a proprietary biostatistical algorithm.

The miR Sentinel Test from miR Scientific, LLC (New York City, NY, USA) is a standalone, non-invasive liquid biopsy urine test that accurately detects, classifies and can monitor prostate cancer at the molecular level. It is intended to aid in the clinical management of men >45 years of age at risk for prostate cancer. miR’s unique sncRNA extraction and interrogation techniques coupled with an advanced proprietary algorithm allow physicians to confidently detect and classify prostate cancers with just one urine sample, eliminating unnecessary treatments for prostate cancer patients.

Validation studies have shown the extraordinary accuracy of miR's molecular prostate cancer detection and classification technology. In a recent clinical study performed at multiple sites within the US and Puerto Rico involving a cohort of ~1100 men, the miR Sentinel Test was shown to identify molecular evidence of prostate cancer in at-risk men with 98.5% sensitivity and distinguish clinically non-significant (nominally No Pathological Evidence of Prostate Cancer and Grade Group 1), from clinically significant prostate cancer (nominally Grade Groups 2-5) with a prognostic sensitivity of 83%.

In a subset analysis of men from this cohort where the findings of TRUS and MRI-guided biopsies disagreed on the presence of prostate cancer, the miR Sentinel Test was able to correctly identify 99% (71/72) of men found positive by either biopsy type while identifying all but four of 234 cases where prostate cancer was found by either TRUS or MRI resulting in a false negative rate of 1.7%. Additionally, 87% of men with PSA levels <3 found to have pathologic grade group 2 through 5 upon biopsy were identified by the miR Sentinel Test as having molecular evidence of intermediate or high risk of aggressive disease. These findings suggest that the miR Sentinel Test may represent a significant improvement over the current standards of care and other tools being used to detect and classify prostate cancer.

The miR Sentinel Prostate Cancer Test is now commercially available in the US, Puerto Rico and select international markets. The current version of the miR SentinelTest represents a refined and clinically validated assessment developed for commercialization based on the company’s comprehensive miR Sentinel PCC4 assay, which has received FDA Breakthrough Device Designation and the original three-test proof of concept.

"We believe that the miR Sentinel Test offers patients and providers a non-invasive means of accurately assessing a man's prostate cancer risk, which could potentially reduce unnecessary biopsies and biopsy-related complications in men with low-risk of clinically significant prostate cancer, while prioritizing diagnostic and treatment resources to those men that potentially harbor clinically significant prostate cancer," said Sam Salman, Chairman and CEO of miR Scientific. "This aligns with miR Scientific's vision to revolutionize prostate cancer disease management by improving accessibility and accuracy of the tools used to assess each man's personal risk of aggressive disease."

Related Links:
miR Scientific, LLC 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.